The stock price of Kura Oncology Inc (NASDAQ: KURA) has surged by 2.19 when compared to previous closing price of 6.38, but the company has seen a -8.68% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-01 that SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 10:30 a.m. ET / 7:30 a.m. PT on April 8, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay following the event.
Is It Worth Investing in Kura Oncology Inc (NASDAQ: KURA) Right Now?
The 36-month beta value for KURA is also noteworthy at 0.50. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for KURA is 75.15M, and at present, short sellers hold a 12.01% of that float. The average trading volume of KURA on April 03, 2025 was 1.46M shares.
KURA’s Market Performance
The stock of Kura Oncology Inc (KURA) has seen a -8.68% decrease in the past week, with a -11.05% drop in the past month, and a -23.38% fall in the past quarter. The volatility ratio for the week is 4.97%, and the volatility levels for the past 30 days are at 5.94% for KURA. The simple moving average for the past 20 days is -10.14% for KURA’s stock, with a -55.10% simple moving average for the past 200 days.
Analysts’ Opinion of KURA
UBS, on the other hand, stated in their research note that they expect to see KURA reach a price target of $27. The rating they have provided for KURA stocks is “Buy” according to the report published on October 24th, 2024.
Stifel gave a rating of “Hold” to KURA, setting the target price at $19 in the report published on October 14th of the previous year.
KURA Trading at -15.91% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.23% of loss for the given period.
Volatility was left at 5.94%, however, over the last 30 days, the volatility rate increased by 4.97%, as shares sank -11.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.77% lower at present.
During the last 5 trading sessions, KURA fell by -8.68%, which changed the moving average for the period of 200-days by -69.77% in comparison to the 20-day moving average, which settled at $7.26. In addition, Kura Oncology Inc saw -25.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from Hasnain Faheem, who sale 22,682 shares at the price of $8.00 back on Mar 21 ’25. After this action, Hasnain Faheem now owns 23,983 shares of Kura Oncology Inc, valued at $181,456 using the latest closing price.
FAHEEM HASNAIN, the Director of Kura Oncology Inc, proposed sale 30,000 shares at $7.85 during a trade that took place back on Mar 21 ’25, which means that FAHEEM HASNAIN is holding shares at $235,500 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -3.17 for the present operating margin
- 0.99 for the gross margin
The net margin for Kura Oncology Inc stands at -3.23. The total capital return value is set at -0.25. Equity return is now at value -42.91, with -23.36 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 8.09. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -105.46.
Currently, EBITDA for the company is -169.5 million with net debt to EBITDA at 1.19. When we switch over and look at the enterprise to sales, we see a ratio of 5.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.46.
Conclusion
In summary, Kura Oncology Inc (KURA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
